-
Publication Venue For
-
Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death.
2022
-
Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
2022
-
Racial and ethnic inequities of palliative care use among advanced Non-Small cell lung cancer patients in the US.
2022
-
Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.
2022
-
Prognostic awareness and its association with health outcomes in the last year of life.
2022
-
Associations between longitudinal changes in sleep disturbance and depressive and anxiety symptoms during the COVID-19 virus pandemic among older women with and without breast cancer in the thinking and living with breast cancer study..
11:3352-3363.
2022
-
Suicide risk following a new cancer diagnosis among Veterans in Veterans Health Administration care.
2022
-
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.
2022
-
Assisted reproductive technology and association with childhood cancer subtypes.
2022
-
Tumor marker response to SARS-CoV-2 infection among patients with cancer..
11:2865-2872.
2022
-
Disparities in telemedicine during COVID-19..
11:1192-1201.
2022
-
Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer..
11:1099-1108.
2022
-
Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma..
11:194-206.
2022
-
Impact of underlying malignancy on emergency department utilization and outcomes..
10:9129-9138.
2021
-
Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma..
10:8891-8898.
2021
-
Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients..
10:7289-7297.
2021
-
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma..
10:6653-6665.
2021
-
Clinical presentation and survival outcomes of well-differentiated thyroid cancer in Filipinos..
10:5964-5973.
2021
-
Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival..
10:3533-3544.
2021
-
The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC..
10:3231-3239.
2021
-
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes..
10:2341-2349.
2021
-
Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk..
9:9620-9631.
2020
-
Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic..
9:9205-9218.
2020
-
A public health approach to cervical cancer screening in Africa through community-based self-administered HPV testing and mobile treatment provision..
9:8701-8712.
2020
-
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study..
9:8468-8479.
2020
-
Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma..
9:8216-8225.
2020
-
Cardiovascular disease, risk factors, and health behaviors among cancer survivors and spouses: A MEPS Study..
9:6864-6874.
2020
-
The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors..
9:5869-5880.
2020
-
Metabolomic effects of androgen deprivation therapy treatment for prostate cancer..
9:3691-3702.
2020
-
Evolution of a longitudinal, multidisciplinary, and scalable patient navigation matrix model..
9:3202-3210.
2020
-
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia..
9:999-1007.
2020
-
A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma..
9:62-76.
2020
-
Connect MM Registry as a national reference for United States multiple myeloma patients..
9:35-42.
2020
-
Outcomes of a randomized controlled trial assessing a smartphone Application to reduce unmet needs among people diagnosed with CancEr (ACE)..
9:507-516.
2020
-
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV..
9:3-11.
2020
-
Operative and peri-operative considerations in the management of brain metastasis..
8:6809-6831.
2019
-
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer..
8:5148-5157.
2019
-
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients..
8:4678-4687.
2019
-
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer..
8:4644-4655.
2019
-
Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation..
8:3325-3335.
2019
-
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women..
8:2503-2513.
2019
-
Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States..
8:374-382.
2019
-
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials..
8:165-173.
2019
-
A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations..
7:4773-4780.
2018
-
Financial burden among older, long-term cancer survivors: Results from the LILAC study..
7:4261-4272.
2018
-
The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation..
7:3257-3268.
2018
-
Impact of pediatric cancer on family relationships..
7:1680-1688.
2018
-
Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer..
7:1183-1193.
2018
-
Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database..
6:320-329.
2017
-
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)..
5:2249-2260.
2016
-
History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC)..
5:1352-1358.
2016
-
Recreational physical activity and ovarian cancer risk in African American women..
5:1319-1327.
2016
-
Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1..
4:1871-1878.
2015
-
ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer..
4:1651-1658.
2015
-
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?.
4:1153-1160.
2015
-
Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009..
4:608-619.
2015
-
A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions..
4:36-42.
2015
-
Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study..
3:667-673.
2014
-
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer..
3:580-591.
2014
-
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study..
3:434-444.
2014
-
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors..
2:316-324.
2013
-
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab..
2:234-242.
2013
-
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma..
2:185-195.
2013
-
Association of diabetes and perineural invasion in pancreatic cancer..
1:357-362.
2012